Search research articles
Contact Us
Filters
Showing results (21-30 of 39) with videos related to
Page
of 4
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
October 6, 2009
Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists
Jack D Scott, Michael W Miller, Sarah W Li, et al.
Journal of Medicinal Chemistry
|
January 2, 2010
Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors
Yu-Sen Wang, Corey Strickland, Johannes H Voigt, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 20, 2005
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED
Craig D Boyle, Ruo Xu, Theodros Asberom, et al.
Journal of Medicinal Chemistry
|
November 3, 2018
Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety
Mihirbaran Mandal, Kaushik Mitra, Diane Grotz, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 7, 2012
Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor
Jared N Cumming, Elizabeth M Smith, Lingyan Wang, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 13, 2014
CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition
Justyna A Dobrowolska, Maria S Michener, Guoxin Wu, et al.
Cancer Research
|
February 26, 2021
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Kamini Singh, Jianan Lin, Nicolas Lecomte, et al.
Journal of Medicinal Chemistry
|
September 20, 2012
Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation
Mihirbaran Mandal, Zhaoning Zhu, Jared N Cumming, et al.
Science Translational Medicine
|
November 4, 2016
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients
Matthew E Kennedy, Andrew W Stamford, Xia Chen, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 13, 2008
Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors
J N Cumming, T X Le, S Babu, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 39) with videos related to
Sort By:
Page
of 4
Bioorganic & Medicinal Chemistry Letters
|
October 6, 2009
Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists
Jack D Scott, Michael W Miller, Sarah W Li, et al.
Journal of Medicinal Chemistry
|
January 2, 2010
Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors
Yu-Sen Wang, Corey Strickland, Johannes H Voigt, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 20, 2005
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED
Craig D Boyle, Ruo Xu, Theodros Asberom, et al.
Journal of Medicinal Chemistry
|
November 3, 2018
Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety
Mihirbaran Mandal, Kaushik Mitra, Diane Grotz, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 7, 2012
Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor
Jared N Cumming, Elizabeth M Smith, Lingyan Wang, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 13, 2014
CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition
Justyna A Dobrowolska, Maria S Michener, Guoxin Wu, et al.
Cancer Research
|
February 26, 2021
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Kamini Singh, Jianan Lin, Nicolas Lecomte, et al.
Journal of Medicinal Chemistry
|
September 20, 2012
Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation
Mihirbaran Mandal, Zhaoning Zhu, Jared N Cumming, et al.
Science Translational Medicine
|
November 4, 2016
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients
Matthew E Kennedy, Andrew W Stamford, Xia Chen, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 13, 2008
Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors
J N Cumming, T X Le, S Babu, et al.
Page
of 4